RPS restructures AdenoPlus licensing agreement

Rapid Pathogen Screening has announced the restructuring of the North American licensing rights to the AdenoPlus test, as well as two diagnostic tests in development.The AdenoPlus test is used to rapidly diagnose adenoviral conjunctivitis to primary and urgent care professionals in the U.S. and is already manufactured and marketed by RPS, according to a company press release.

Full Story →